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Background & Objectives: Poor bioavailability of rifampicin (R) in combination with other
anti-tuberculosis drugs such as isoniazid (H), pyrazinamide (Z), and ethambutol (E) is a subject of
much concern for the last few decades. This could be due to an interaction between R and other drugs.
An investigation was therefore undertaken to examine the bioavailability of R in the presence of H, Z
and E or a combination of the three drugs.
Methods: The study included eight healthy volunteers, each being investigated on four occasions at
weekly intervals once with R alone and with three of the four combinations on the three remaining
occasions. A partially balanced incomplete block design was employed and the allocation of R or the
drug combinations was random. Plasma concentrations of R at intervals upto 12 h were determined by
microbiological assay using Staphylococcus aureus as the test organism. The proportion (%) dose of R
as R plus desacetyl R (DR) in urine excreted over the periods 0-8 and 8-12 h was also determined.
Bioavailability was expressed as an index (BI) of area under time concentration curve (AUC) calculated
from the plasma concentrations or proportion of dose of R excreted as R plus DR in urine with the
combinations to that with R alone.
Results: The bioavailability indices based on AUC were 0.96 with RE, 0.76 with RH, 1.08 with RZ and
0.65 with REHZ. The indices based on urine estimations (0-8 h) were similar, the values being 0.94,
0.84, 0.94 and 0.75, respectively. A second investigation revealed that the decrease of bioavailability of
R with H was not due to the excipients present in H tablets.
Interpretation & conclusion: Isoniazid alone or in combination with E and Z reduces the bioavailability
of R. Urinary excretion data offer a simple and non invasive method for the assessment of bioavailability
of R.
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Current treatment of tuberculosis involves the use of
multiple drug regimens containing rifampicin (R) in addition
to ethambutol (E), isoniazid (H) and pyrazinamide (Z).
Bioavailability of R is known to be affected by a number
of factors such as the manufacturing process1, presence
of food in the gastrointestinal tract2, acidity of the gastric
juice3 and excipients including those used with companion
drugs such as p-amino salicylic acid4. Ethambutol has been
shown to have little or no effect on the gastrointestinal
absorption of R5 and concomitant administration of Z
resulted in a lower bioavailability of R6. Published results
with respect to H are equivocal. While Boman et al7 and
Acocella et al8 did not observe any effect, Mouton
et al9 demonstrated a decrease in the plasma
concentrations of R when administered together with H.
In normal adults the peak plasma concentrations after
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administration of 600 mg R, are in the range of
6-13 µg /ml, while on administration of R along with H
and/or Z, the peak concentrations range from 3-6 µg/ml
and AUC0-8 values in the range of 30-50 µg/ml.h10-12.
Shishoo et al13 demonstrated decreased bioavailability of
R in presence of H both by means of in vitro dissolution
testing and in vivo bioavailability studies. Grosset et al14
observed an antagonism between R and H in experimental
murine tuberculosis and attributed this to a decreased
bioavailability of R. To gain a better understanding of the
interactions if any, an investigation was done to study the
bioavailability of R when administered together with E, H,
Z or a combination of the three drugs (EHZ). The
conclusions are not only based on the traditional plasma
levels (AUC), but also on the excretion of the proportion
of the administered drug as R plus its primary metabolite,
desacetyl rifampicin (DR) in urine. Since the results of
this investigation revealed a significant decrease in the
bioavailability of R when administered together with H
alone or EHZ, another investigation based on urine
excretion of R plus DR was undertaken to examine
whether it was H per se or the excipients present in
H tablets that was  responsible for the decrease.
Material & Methods
The investigations were undertaken in healthy male
volunteers (college students and the centre staff) aged
18-56 yr with normal, hepatic and renal function.
Rifampicin (Tata Pharma, India), ethambutol
(Ciba-Geigy, India), isoniazid (Pfizer, India) and
pyrazinamide (Lupin, India) were used in the first
investigation. In the second investigation, due to the non-
availability of the Tata Pharma Product, rifampicin
(Lupin) was used and pure isoniazid powder was a Bayer
product. Standard dosages of the drugs15 were used in
the investigations: 10 mg/kg body weight for R,
25 mg/kg for E, 12 mg/kg for H and 35 mg/kg for Z.
The investigations were started after getting approval
from the institutional ethics committee and informed
written consent from all the study subjects.
Plasma R concentrations were determined by the plate
diffusion assay of Dickinson et al16 employing a strain
of Staphylococcus aureus [Sub Group I - NCTC 10702,
a gift from Dr DA Mitchison, British Medical Research
Council (BMRC), UK], resistant to streptomycin and
other antibiotics. Rifampicin standards ranging from
0.04-1.28 µg/ml were set up in quadruplicate and the
concentrations of the drug in plasma (set up in
quadruplicate in dilutions of 1 in 5, 1 in 10 and 1 in 20)
were obtained from regression line of zone of inhibition
on log concentrations of the standards.
Urinary excretion of R plus DR was estimated
according to the procedure of Immanuel et al17. In brief,
urine samples (3ml or larger according to volume
excreted) and standard concentrations of R ranging from
10-50 µg/ml set up in normal urine were mixed with
1.5 ml of a citrate - phosphate buffer, pH 7.0 and
extracted with 3 ml of chloroform. The extinction of the
chloroform extract was recorded at 475 nm giving an
estimate of the concentrations of R plus DR without
interference from other metabolites of R.
Conduct of the investigations:
Investigation I–A total of eight volunteers were
investigated. Each volunteer was investigated on four
occasions, once with R alone (control) and with 3 of the
4 drug combinations, RE, RH, RZ and REHZ on the
other three occasions with an interval of at least one
week between occasions. A partially balanced
incomplete block design was employed and by using this
design, information on R alone was available for all the
8 subjects and for 6 each with the four drug combinations.
The sequence of administration of R and the combinations
was random (Table I).
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Table I. Sequence of administration of R alone and in combination
with E, H and Z
            Occasions
Volunteer I II III IV
No.
1. RE REHZ R RH
2. R REHZ RE RZ
3. R RH RZ RE
4. REHZ R RH RZ
5. RZ RH R REHZ
6. RZ RE REHZ R
7. RH R REHZ RE
8. RH RZ RE R
R (n=8);  RE, RH, RZ & REHZ (n=6)
R, rifampicin;  E, ethambutol;   H, isoniazid;  Z, pyrazinamide
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About eight ml of heparinised blood was collected at
1, 2, 3, 6, 9 and 12 h after administration of drug(s) and
total urine excreted over the periods 0-8 and 8-12 h were
collected following drug administration on an empty
stomach. Uniform breakfast and lunch were provided
at the end of 2 and 6 h respectively after drug
administration. Plasma was separated and stored along
with aliquots of urine at -20°C until analysis. Estimations
of plasma R concentrations and those of R plus DR in
urine were undertaken within 48 h.
Investigation II–Six volunteers were investigated on two
occasions. On the first occasion, 3 volunteers received
R (10 mg/kg) plus pure H powder (12 mg/kg), while the
other 3 received R plus H tablet in the same dosage. On
the second occasion, a week later, the order of
administration of H powder or the tablet was reversed, a
cross-over design being employed. Urine excreted over
the period (0-8 h) was collected and the proportion (%) of
the dose of R excreted as R plus DR was calculated.
In both the investigations, all estimations were
undertaken after randomising and coding the samples.
In investigation-I comparison of the values between
the control group (R only) and those who received
RE, RH,  or REHZ was restricted to the same subjects
who received the particular combination and the
control.
Pharmacokinetics and statistical analysis: Maximum
concentration (C
max





were determined by direct visual inspection of data.
Linear trapezoidal rule was used to calculate area under
time concentration curve (AUC0-12)18. The elimination
rate constant (Kel) was calculated from the terminal
log-linear decline of concentration. Terminal elimination
half-life (t½) was calculated as 0.693/Kel.
The bioavailability of R for each of the 4 drug
combinations has been expressed as an index (BI) and
is the ratio of AUC or the proportion of the dose excreted
as R plus DR in urine with the four combinations
(RE, RH, RZ and REHZ) to the respective control values
obtained after the administration of R alone. Student’s
t-test (paired and unpaired) was used for testing the
significance of the differences between the mean values.
Results
Investigation I: The mean body weight of the
8 volunteers was 66.1 kg±SD (range 56.5-75.4 kg) and
the mean dosages of R administered to the RE, RH, RZ
and REHZ groups (and the respective controls) were
10.88, 11.43, 11.30 and 10.86 mg/kg, respectively.
The mean serial plasma R concentrations for all the
8 control subjects (R only) and for 6 each with RE, RH,
RZ and REHZ are shown in the Fig. The mean peak
concentrations and AUC0-12 calculated from those
concentrations together with the proportion (%) of dose
excreted as R plus DR in urine over the periods 0-8 and
0-12 h are presented in Table II.
Peak concentrations were attained before the third
hour in all the subjects and the concentrations fell
exponentially thereafter with mean half-lives ranging from
4.14 in the RZ group to 5.14 in the REHZ group, none of
these differences being significant. Administration of
E or Z did not appear to have any significant effect on
the plasma concentrations or the urinary excretion of R.
However, the C
max
 and the AUC values were significantly
lower in the RH (24%) and REHZ (39%) groups than in
the respective controls who received R only (P<0.01).
Corresponding to the above, the proportion (%) of dose
excreted as R plus DR was lower in RH and REHZ
groups than in the respective controls, the decrease with
RH and REHZ being 18 and 25 per cent over the 0-8 h
period and 15 and 21 per cent respectively over a 12h
period, all the differences being significant (P<0.01)
(Table II).
None of the differences in the mean values of C
max
,
AUC0-12 or the proportion of dose excreted as R plus
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Fig. Plasma concentrations of rifampicin in different study groups.
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DR in urine was significant between the RE and the RZ
groups or between the RE and the RH groups. Only the
mean AUC0-12 value of R was significantly higher in the
RZ group than in the RH group (P=0.02). The mean
values of all the variables in the RE and the RZ groups
were, however, significantly higher than those in the
REHZ group (P<0.03). Even though the mean values of
all the variables were lower in the REHZ group than in
the RH group too, non of the differences was significant.
The BI (based on AUC and per cent dose excreted
in urine) of RE and RZ groups were significantly higher
than those obtained for the RH and REHZ groups
(P<0.05). The mean values were consistently higher with
RH than with REHZ, but none of these differences was
significant (Table III).
Investigation II: The mean proportions of the dose of R
excreted as R plus DR in urine excreted over the period
0-8 h were 9.3 per cent with R plus pure H powder and
10.6 per cent with R plus H tablets; the difference was
not significant.
Discussion
Good bioavailability leading to adequate plasma and
tissue concentrations of R (and other drugs) is an
absolute prerequisite for the success of treatment of
tuberculosis. It has been postulated that peak plasma R
concentrations should be of the order of 10-15 µg/ml
with dosages of 10-12 mg/kg for good therapeutic
response19. Together with Z, R is one of the key sterilizing
drugs and its anti-TB potency is markedly dose
dependent20. A United States Public Health System
(USPHS) trial has shown that with lower dosages such
as 9 mg/kg leading to lower plasma concentrations of R,
Table II. Pharmacokinetics of R given alone and in different combinations
                     Groups
Pharmacokinetic R vs RE R vs RH R vs RZ R vs REHZ
variable
R RE R RH R RZ R REHZ
Plasma : 11.9 12.7 13.5 11.1* 13.8 14.5 13.6 7.9*
Peak concentration ±3.4 ±1.8 ±4.3 ±3.8 ±3.0 ±1.7 ±4.2 ±2.4
(µg/ml)
AUC0-12 72.4 64.6 77.3 58.6* 79.7 85.6 73.1 44.6*
(µg/ml.h) ±20.0 ±4.4 ±22.1 ±16.7 ±22.1 ±15.3 ±20.4 ±11.2
Urine :
% dose excreted 12.8 11.8 14.1 11.9* 13.1 13.7 12.6 9.5*
0-8 h ±2.3 ±1.1 ±1.8 ±2.0 ±2.2 ±2.1 ±2.0 ±2.1
% dose excreted 17.5 16.0 19.3 16.4* 18.4 17.0 16.8 13.2*
0-12 h ±3.8 ±2.2 ±2.7 ±2.5 ±3.6 ±3.3 ±2.9 ±2.9
Values are mean±SD. n=8 for group R;  n=6 for groups RE, RH, RZ and REHZ
*P<0.01 compared to R
Table III. Bioavailability indices for the various groups




AUC0-12 0-8 h 0-12 h
RE 0.96±0.32 0.94±0.12 0-94±0.17
RZ 1.08±0.20 0.94±0.07 0.94±0.10
RH 0.76±0.11* 0.84±0.08 0.85±0.07*
REHZ 0.65±0.25* 0.75±0.09 0.65±0.25*
Values are mean ± SD.  n=8 for group R; n=6 for groups RE, RH, RZ
and REHZ; * P<0.05 compared to RE and RZ
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the speed at which sputum conversion occurs is also
reduced21.
Evidence presented in this report suggests that H alone
or in combination with E and Z reduces the bioavailability
of R. Since the plasma elimination half-lives were similar
with the different combinations employed, this could result
only from a decreased gastrointestinal absorption of R
caused by H. Impaired bioavailability of R in the
presence of H as seen in the present study could be
due to degradation of R in the presence of H as reported
by Jindal et al22 by in vitro disssolution testing. Similar
results have been reported by Shishoo et al23 who
showed more degradation of  R in combination with
H (18-21%). They have further observed that after
oral administration of R and H together, an appreciable
amount of R is degraded in the acidic conditions of the
stomach to 3-formyl rifampicin (3-FR), which is not
absorbed and is inactive. 3-formyl rifampicin undergoes
a reversible reaction to form a hydrazone with H. As a
result, decomposition of R to 3-FR is pushed forward
and an overall increase in the degradation of R is
observed in the presence of H13. This observation is in
agreement with that of Singh and co-workers24, who
demonstrated degradation of R in the presence of H
using a specific HPLC method showing a 3-FR hydrazone
peak in the HPLC analysis which was  confirmed with
a synthetic 3-FR hydrazone.
The results of the second investigation show that it is
H per se and not the excipient present in H tablet, that is
responsible for the decrease in the absorption of R. These
findings are in agreement with those reported earlier 9,14.
Further, our observation that Z does not affect the
bioavailability of R contradicts the findings of
Jain et al6. Whether the decreased bioavailability of R
exerts any therapeutic penalty in the presence of three
other powerful anti-tuberculosis drugs during the initial
intensive phase of treatment is a matter of conjecture.
Combining H with R during the continuation phase is
unlikely to have any deleterious effect as there would
have been a substantial reduction in the bacterial load
by then.
We also examined the bioavailability of E, H and Z in
a total of 17 healthy individuals (including the 8 volunteers
in the first investigation of this study). Results
(not reported) showed that concomitant administration
of the other drugs either alone or in combination did not in
any way, affect the bioavailability of E, H or Z. This finding
is in agreement with that reported by other workers25-27.
About 20 per cent of the administered dose of R is
excreted as R plus DR over a 24 h period
(TRC, unpublished findings). Of this, more than
70 per cent (i.e. about 14% of the dose) is excreted during
the first 8 h period. Determination of plasma R
concentrations is a complex process and the variation
associated with these determinations is larger than that
with the estimations of R plus DR in urine. Thus, on the
basis of the results obtained in the eight volunteers
following administration of  R alone, the coefficient of
variation associated with the AUC values (based on the
determination of plasma concentrations) was 24.9 per cent
as against coefficient of variations of 16.1 and 18.7 per
cent with the estimation of R plus DR in urine collected
over the periods 0-8 and 0-12 h respectively. Thus, the
urine method reported in this paper, provides bioavailability
indices similar to those based on plasma concentrations,
which is in agreement with that reported by others28-30.
The urine method, therefore, offers a simple and reliable
non invasive procedure for investigations requiring an
assessment of the bioavailability of  R in double and triple
drug formulations containing the drug.
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